Abstract 418P
Background
Mutational landscape studies, facilitated by next-generation sequencing technologies, can improve our understanding of cancer pathogenesis and help identify potentially targetable alterations. In this study, we aimed to provide an overall description of the mutational landscape in non-small cell lung cancer (NSCLC) using publicly available sequencing data.
Methods
We used the American Association for Cancer Research’s Project Genomics Evidence Neoplasia Information Exchange (GENIE) [GENIE Cohort v11.0-public study] to obtain sequencing data for patients diagnosed with NSCLC. Mutational profiles were described according to race (White, Black, or Asian) and histopathology (adenocarcinoma or squamous cell carcinoma). We used the OncoKB to assess the actionability of frequently mutated genes in the studied cohort.
Results
We included 16,498 samples (13,927 White, 1,304 Black, and 1,267 Asian; 12,790 adenocarcinoma, and 1,546 squamous cell carcinoma). TP53 was the most frequently mutated gene, with half of the analyzed samples (49.6%) containing at least one TP53-related molecular alteration. TP53 mutation rate was higher in cases with squamous cell carcinoma compared to cases with adenocarcinoma (76.7% vs. 45.6%; p<0.001). In race-dependent subgroup analysis, mutations in EGFR gene occurred in about 53.3% of Asian cases to rank as the most frequently mutated gene in this subgroup (Table). Most of the frequently mutated genes in NSCLC (especially in the squamous cell carcinoma subgroup) are still not actionable (Table). Table: 418P
Commonly mutated genes in NSCLC
Adenocarcinoma | Squamous Cell | White | Black | Asian |
TP53 (45.6%) | TP53 (76.6%) | TP53 (49.2%) | TP53 (55.7%) | EGFR (53.3%) * |
KRAS (32.2%) * | KMT2D (22.1%) | KRAS (30%) * | PCM1 (25%) | TP53 (48.2%) |
EGFR (25.8%) * | PRKDC (11.5%) | EGFR (18.8%) * | KRAS (24.8%) * | KRAS (10.6%) * |
KEAP1 (13.5%) | PCM1 (11.3%) | KEAP1 (14.6%) | EGFR (20.6%) * | RBM10 (9.5%) |
SKT11 (13.1%) * | KEAP1 (11%) | LRP1B (13%) | KEAP1 (11.8%) | KMT2D (6.9%) |
* gene with actionable mutation(s)
Conclusions
Despite progress in the targetability of NSCLC, many of the most frequently mutated genes are still not actionable. Genomic profiling has the potential to identify potential targets of interest, which could guide individualized treatment plans to address the current high burden of NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
399P - Role of denosumab as targeted therapy in treatment of unresectable or recurrent cases of giant cell tumor of the bone
Presenter: Anchal Mishra
Session: Poster viewing 06
400P - Phase I study of fianlimab, a human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced melanoma (mel)
Presenter: Omid Hamid
Session: Poster viewing 06
401P - A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors
Presenter: Shunsuke Kondo
Session: Poster viewing 06
402P - Phase I study of selumetinib in Chinese pediatric and adult patients (pts) with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN): Interim results
Presenter: Xiao-Jun Yuan
Session: Poster viewing 06
403P - Gender trend over time of principal investigators within large Australian cancer clinical trials groups
Presenter: Thi Thao Vi Luong
Session: Poster viewing 06
404P - Adolescent & young adult cancers (AYA): Experience from a large rural teaching hospital in South India
Presenter: Vishwapriya Godkhindi
Session: Poster viewing 06
405P - Evaluating medical oncology outcomes (EMOO) in Asia study: Diagnosis, staging, treatment patterns and outcome of patients with lung cancer registered 2017-2019
Presenter: Ross Soo
Session: Poster viewing 06
406P - Adrenal insufficiency induced by immune checkpoint inhibitors: Clinical characteristics of 145 cases
Presenter: kaoru koshiba
Session: Poster viewing 06
407P - A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan
Presenter: Naoya Yamazaki
Session: Poster viewing 06
408P - Machine learning for glioblastoma screening from histopathology whole slide imaging
Presenter: Eva Yi Wah Cheung
Session: Poster viewing 06